NCT06527521 Prevalence of Amyloidosis in Trauma Patients
| NCT ID | NCT06527521 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Consorci Sanitari de l'Alt Penedès i Garraf |
| Condition | Amyloidosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 246 participants |
| Start Date | 2024-11-13 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 246 participants in total. It began in 2024-11-13 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to determine the frequency of amyloidosis among patients undergoing trauma surgery.
Eligibility Criteria
Inclusion Criteria: * Men and women included in the waiting list for scheduled trauma surgery with at least one of the following criteria defined as red flags: Over 65 years old; Possible family history of amyloidosis, Cardiac pathology: aortic stenosis, presence of left ventricular hypertrophy defined as interventricular septal thickness \> 12mm measured by echocardiography, history of previous brady- or tachyarrhythmias including cardiac conduction blocks, history of syncope or presyncope, pro BNP \> 300 in previous blood tests; History of sensory peripheral neuropathy; History of nephropathy without etiological diagnosis; History of liver disease without a clear cause. * Ability to cooperate in the necessary evaluations. * Signed informed consent for inclusion in the study, either by the participant or their legal representative. Exclusion Criteria: \- Participants previously diagnosed with amyloidosis cannot be included in the study.
Contact & Investigator
Lidia Tikhomirova, MD
PRINCIPAL INVESTIGATOR
CSAPG
Frequently Asked Questions
Who can join the NCT06527521 clinical trial?
This trial is open to participants of all sexes, studying Amyloidosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06527521 currently recruiting?
Yes, NCT06527521 is actively recruiting participants. Contact the research team at ltikhomirova@csapg.cat for enrollment information.
Where is the NCT06527521 trial being conducted?
This trial is being conducted at Sant Pere de Ribes, Spain.
Who is sponsoring the NCT06527521 clinical trial?
NCT06527521 is sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. The principal investigator is Lidia Tikhomirova, MD at CSAPG. The trial plans to enroll 246 participants.